Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Johnson and Johnson

Last Updated: November 29, 2021

DrugPatentWatch Database Preview

Patent: 7,361,740

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 7,361,740
Title:Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
Abstract: The present invention provides for a modified antibody of class IgG, in which at least one amino acid from the heavy chain constant region selected from the group consisting of amino acid residues 250, 314, and 428 is substituted with another amino acid which is different from that present in the unmodified antibody, thereby altering the binding affinity for FcRn and/or the serum half-life in comparison to the unmodified antibody.
Inventor(s): Hinton; Paul R. (Sunnyvale, CA), Tsurushita; Naoya (Palo Alto, CA), Tso; J. Yun (Menlo Park, CA), Vasquez; Maximiliano (Palo Alto, CA)
Assignee: PDL BioPharma, Inc. (Redwood City, CA)
Application Number:10/822,300
Patent Claims:see list of patent claims

Details for Patent 7,361,740

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Hoffmann-la Roche Inc. ZENAPAX daclizumab Injection 103749 1997-12-10 ⤷  Try it Free 2022-10-15
Biogen Inc. ZINBRYTA daclizumab Injection 761029 2016-05-27 ⤷  Try it Free 2022-10-15
Biogen Inc. ZINBRYTA daclizumab Injection 761029 2017-05-26 ⤷  Try it Free 2022-10-15
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.